Myriad Genetics Company Profile (NASDAQ:MYGN)

About Myriad Genetics (NASDAQ:MYGN)

Myriad Genetics logoMyriad Genetics, Inc. is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to enable optimal treatment, or assess a patient's risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services, such as finance, human resources, legal and information technology. Its molecular diagnostic tests include myRisk Hereditary Cancer, BRACAnalysis CDx and COLARIS.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Diagnostic & Testing Equipment
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:MYGN
  • CUSIP: 62855J10
  • Web:
  • Market Cap: $2.35 billion
  • Outstanding Shares: 69,207,000
Average Prices:
  • 50 Day Moving Avg: $34.26
  • 200 Day Moving Avg: $25.96
  • 52 Week Range: $15.15 - $37.30
  • Trailing P/E Ratio: 107.96
  • Foreward P/E Ratio: 28.90
  • P/E Growth: 3.17
Sales & Book Value:
  • Annual Revenue: $771.4 million
  • Price / Sales: 3.09
  • Book Value: $11.38 per share
  • Price / Book: 3.02
  • EBITDA: $97.7 million
  • Net Margins: 2.83%
  • Return on Equity: 9.67%
  • Return on Assets: 5.75%
  • Debt-to-Equity Ratio: 0.13%
  • Current Ratio: 1.46%
  • Quick Ratio: 1.26%
  • Average Volume: 975,952 shs.
  • Beta: 0.28
  • Short Ratio: 25.37

Frequently Asked Questions for Myriad Genetics (NASDAQ:MYGN)

What is Myriad Genetics' stock symbol?

Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN."

How were Myriad Genetics' earnings last quarter?

Myriad Genetics, Inc. (NASDAQ:MYGN) announced its quarterly earnings results on Tuesday, August, 8th. The company reported $0.30 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.26 by $0.04. The company earned $200.50 million during the quarter, compared to the consensus estimate of $193.71 million. Myriad Genetics had a net margin of 2.83% and a return on equity of 9.67%. The firm's quarterly revenue was up 7.5% compared to the same quarter last year. During the same quarter last year, the firm earned $0.36 earnings per share. View Myriad Genetics' Earnings History.

When will Myriad Genetics make its next earnings announcement?

Myriad Genetics is scheduled to release their next quarterly earnings announcement on Monday, October, 30th 2017. View Earnings Estimates for Myriad Genetics.

What guidance has Myriad Genetics issued on next quarter's earnings?

Myriad Genetics issued an update on its FY18 earnings guidance on Tuesday, August, 8th. The company provided EPS guidance of $1.00-1.05 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.08. The company issued revenue guidance of $750-770 million, compared to the consensus revenue estimate of $789.30 million.Myriad Genetics also updated its Q1 guidance to $0.19-0.21 EPS.

Where is Myriad Genetics' stock going? Where will Myriad Genetics' stock price be in 2017?

10 brokerages have issued 12-month price objectives for Myriad Genetics' stock. Their predictions range from $15.00 to $40.00. On average, they anticipate Myriad Genetics' stock price to reach $24.67 in the next year. View Analyst Ratings for Myriad Genetics.

What are analysts saying about Myriad Genetics stock?

Here are some recent quotes from research analysts about Myriad Genetics stock:

  • 1. According to Zacks Investment Research, "Over the last three months, Myriad Genetics has been trading above the broader industry. While we await the company to release its first quarter fiscal 2018 results, we expect it to deliver another quarter of strong topline on the back of solid growth in EndoPredict and GeneSight testing revenues. Also, the company witnessed a third consecutive quarter of rise in hereditary cancer volumes. We are currently upbeat about the receipt of positive coverage decision for EndoPredict tests from Palmetto GBA. Also, it received provincial reimbursement in Quebec for the same.  Recently, the company introduced riskScore under its myRisk Hereditary Cancer testing portfolio.  On the flip side, a dull operating margin scenario owing to a rise in operating expenses is disappointing. Currency fluctuations and stiff competition are other major headwinds for the company." (10/17/2017)
  • 2. Cowen and Company analysts commented, "The FDA approved Tesaro's niraprarib (Zejula) yesterday. This approval was not limited to mutational status, and therefore does not require MYGN's myChoice HRD test. This outcome is consistent with our thoughts since last June, and as a result has limited impact to our MYGN financial forecast." (3/28/2017)

Who are some of Myriad Genetics' key competitors?

Who are Myriad Genetics' key executives?

Myriad Genetics' management team includes the folowing people:

  • John T. Henderson M.D., Independent Chairman of the Board
  • Mark C. Capone, President, Chief Executive Officer, Director
  • Walter M. Gilbert Ph.D., Independent Vice Chairman of the Board
  • R. Bryan Riggsbee CPA, Chief Financial Officer, Treasurer
  • Virginia C. Drosos, President of Assurex Health, Inc.
  • Alexander Ford, President of Myriad Genetic Laboratories, Inc.
  • Ralph L. McDade Ph.D., President of Myriad RBM, Inc
  • Bernard F. Tobin, President of Crescendo Bioscience, Inc
  • Richard M. Marsh Esq., Executive Vice President, General Counsel, Secretary
  • Gary A. King, Executive Vice President - International Operations

Who owns Myriad Genetics stock?

Myriad Genetics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Eqis Capital Management Inc. (0.04%). Company insiders that own Myriad Genetics stock include Alexander Ford, Gary A King, Heinrich Dreismann, Jerry S Lanchbury, John T Henderson, Mark Christopher Capone, Ralph L Mcdade, Richard M Marsh, S Louise Phanstiel and Walter Phd Gilbert. View Institutional Ownership Trends for Myriad Genetics.

Who sold Myriad Genetics stock? Who is selling Myriad Genetics stock?

Myriad Genetics' stock was sold by a variety of institutional investors in the last quarter, including Eqis Capital Management Inc.. View Insider Buying and Selling for Myriad Genetics.

How do I buy Myriad Genetics stock?

Shares of Myriad Genetics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Myriad Genetics' stock price today?

One share of Myriad Genetics stock can currently be purchased for approximately $34.39.

MarketBeat Community Rating for Myriad Genetics (NASDAQ MYGN)
Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  261 (Vote Outperform)
Underperform Votes:  437 (Vote Underperform)
Total Votes:  698
MarketBeat's community ratings are surveys of what our community members think about Myriad Genetics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Myriad Genetics (NASDAQ:MYGN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Sell Ratings, 7 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 1.90)
Consensus Price Target: $24.67 (28.27% downside)
Consensus Price Target History for Myriad Genetics (NASDAQ:MYGN)
Price Target History for Myriad Genetics (NASDAQ:MYGN)
Analysts' Ratings History for Myriad Genetics (NASDAQ:MYGN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/6/2017Morgan StanleyReiterated RatingUnderweight$17.00 -> $24.00N/AView Rating Details
10/2/2017Leerink SwannReiterated RatingMkt Perform -> Market Perform$31.00MediumView Rating Details
9/22/2017StephensReiterated RatingOverweight$36.00 -> $40.00LowView Rating Details
9/17/2017Cowen and CompanyReiterated RatingHold$25.00LowView Rating Details
8/18/2017Deutsche Bank AGUpgradeSell -> Hold$27.86 -> $15.00HighView Rating Details
8/10/2017Jefferies Group LLCReiterated RatingHold$21.00 -> $23.00HighView Rating Details
8/9/2017Barclays PLCLower Price TargetEqual Weight$28.00 -> $26.00HighView Rating Details
7/14/2017Piper Jaffray CompaniesReiterated RatingHold$22.00LowView Rating Details
6/30/2017J P Morgan Chase & CoReiterated RatingUnderweight$16.00LowView Rating Details
2/8/2017Ladenburg Thalmann Financial ServicesUpgradeSell -> NeutralN/AView Rating Details
10/10/2016Bank of America CorporationReiterated RatingSellN/AView Rating Details
8/21/2016Wells Fargo & CompanyUpgradeMarket Perform -> OutperformN/AView Rating Details
8/10/2016GabelliDowngradeBuy -> Hold$46.00 -> $32.00N/AView Rating Details
8/10/2016MizuhoLower Price TargetNeutral$34.00 -> $22.00N/AView Rating Details
5/4/2016Avondale PartnersLower Price TargetMarket Outperform$50.00 -> $47.00N/AView Rating Details
3/23/2016Goldman Sachs Group, Inc. (The)Boost Price Target$40.00N/AView Rating Details
(Data available from 10/19/2015 forward)


Earnings History for Myriad Genetics (NASDAQ:MYGN)
Earnings by Quarter for Myriad Genetics (NASDAQ:MYGN)
Earnings History by Quarter for Myriad Genetics (NASDAQ MYGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/30/2017$0.21N/AView Earnings Details
8/8/2017Q4 17$0.26$0.30$193.71 million$200.50 millionViewListenView Earnings Details
5/2/2017Q3 2017$0.24$0.27$188.89 million$196.90 millionViewListenView Earnings Details
2/7/2017Q2 2017$0.24$0.26$189.72 million$196.50 millionViewListenView Earnings Details
11/1/2016Q117$0.26$0.23$172.31 million$177.50 millionViewN/AView Earnings Details
8/9/2016Q416$0.38$0.36$187.95 million$186.50 millionViewN/AView Earnings Details
5/3/2016Q316$0.38$0.41$185.08 million$190.50 millionViewN/AView Earnings Details
2/2/2016Q216$0.41$0.45$189.99 million$193.30 millionViewN/AView Earnings Details
11/3/2015Q116$0.35$0.41$177.89 million$183.50 millionViewN/AView Earnings Details
8/11/2015Q415$0.42$0.41$187.81 million$189.90 millionViewListenView Earnings Details
5/5/2015Q315$0.39$0.40$183.30 million$180.00 millionViewListenView Earnings Details
2/3/2015Q215$0.35$0.40$183.41 million$184.40 millionViewListenView Earnings Details
11/4/2014Q115$0.33$0.25$175.00 million$168.84 millionViewListenView Earnings Details
8/12/2014Q414$0.46$0.48$187.68 million$188.80 millionViewListenView Earnings Details
5/6/2014Q314$0.45$0.60$175.23 million$182.92 millionViewListenView Earnings Details
2/4/2014Q214$0.46$0.66$176.02 million$204.06 millionViewListenView Earnings Details
11/5/2013Q114$0.46$0.68$167.64 million$202.50 millionViewN/AView Earnings Details
8/13/2013Q4 2013$0.44$0.53$159.87 million$174.10 millionViewN/AView Earnings Details
5/7/2013Q3 2013$0.39$0.46$148.25 million$156.40 millionViewN/AView Earnings Details
2/5/2013Q2 2013$0.38$0.42$143.71 million$140.70 millionViewN/AView Earnings Details
11/5/2012Q113$0.32$0.36$129.84 million$133.40 millionViewN/AView Earnings Details
8/14/2012$0.34$0.34ViewN/AView Earnings Details
5/1/2012$0.32$0.34ViewN/AView Earnings Details
1/31/2012$0.31$0.33ViewN/AView Earnings Details
11/1/2011$0.27$0.29ViewN/AView Earnings Details
8/9/2011$0.29$0.30ViewN/AView Earnings Details
5/3/2011$0.25$0.31ViewN/AView Earnings Details
1/27/2011$0.26$0.26ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Myriad Genetics (NASDAQ:MYGN)
2017 EPS Consensus Estimate: $1.25
2018 EPS Consensus Estimate: $1.02
2019 EPS Consensus Estimate: $1.11
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.25$0.42$0.31
Q2 20173$0.23$0.46$0.33
Q3 20173$0.24$0.43$0.31
Q4 20173$0.26$0.38$0.30
Q1 20183$0.19$0.21$0.20
Q2 20183$0.21$0.26$0.24
Q3 20183$0.26$0.27$0.26
Q4 20183$0.31$0.33$0.32
Q1 20193$0.22$0.26$0.25
Q2 20193$0.23$0.28$0.26
Q3 20193$0.28$0.29$0.29
Q4 20193$0.29$0.35$0.31
(Data provided by Zacks Investment Research)


Dividend History for Myriad Genetics (NASDAQ:MYGN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Myriad Genetics (NASDAQ:MYGN)
Insider Ownership Percentage: 6.70%
Insider Trades by Quarter for Myriad Genetics (NASDAQ:MYGN)
Institutional Ownership by Quarter for Myriad Genetics (NASDAQ:MYGN)
Insider Trades by Quarter for Myriad Genetics (NASDAQ:MYGN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/1/2017John T HendersonDirectorSell30,000$30.30$909,000.00View SEC Filing  
2/23/2017John T HendersonDirectorBuy6,000$18.66$111,960.00View SEC Filing  
9/12/2016John T HendersonDirectorSell30,000$20.49$614,700.00View SEC Filing  
8/19/2016Mark Christopher CaponeInsiderBuy10,000$21.24$212,400.00View SEC Filing  
8/12/2016Ralph L McdadeInsiderBuy1,000$21.49$21,490.00View SEC Filing  
6/21/2016Alexander FordInsiderSell18,637$30.87$575,324.19View SEC Filing  
4/6/2016Gary A KingVPSell15,000$39.03$585,450.00View SEC Filing  
4/1/2016Gary A KingVPSell15,000$38.12$571,800.00View SEC Filing  
12/11/2015Walter Phd GilbertDirectorSell5,000$42.23$211,150.00View SEC Filing  
12/8/2015S. Louise PhanstielDirectorSell5,000$44.00$220,000.00View SEC Filing  
11/5/2015Heinrich DreismannDirectorSell60,000$44.44$2,666,400.00View SEC Filing  
11/4/2015Richard M. MarshVPSell35,000$44.50$1,557,500.00View SEC Filing  
10/28/2015Gary A. KingVPSell10,000$42.82$428,200.00View SEC Filing  
10/28/2015Jerry S. LanchburyinsiderSell50,962$41.86$2,133,269.32View SEC Filing  
10/27/2015Jerry S. LanchburyinsiderSell24,767$41.80$1,035,260.60View SEC Filing  
9/17/2015Jerry S. LanchburyinsiderSell60,270$39.89$2,404,170.30View SEC Filing  
9/16/2015Richard M. MarshVPSell35,000$41.25$1,443,750.00View SEC Filing  
9/14/2015Gary A. KingVPSell14,562$39.41$573,888.42View SEC Filing  
9/3/2015Gary A. KingVPSell25,438$39.41$1,002,511.58View SEC Filing  
9/2/2015Gary A. KingVPSell15,000$38.23$573,450.00View SEC Filing  
8/28/2015Gary A. KingVPSell30,000$35.73$1,071,900.00View SEC Filing  
11/3/2014Gary A KingVPSell6,568$39.95$262,391.60View SEC Filing  
9/30/2014James S EvansCFOSell21,850$38.99$851,931.50View SEC Filing  
9/24/2014James S EvansCFOSell8,790$37.98$333,844.20View SEC Filing  
9/23/2014James S EvansCFOSell110,463$37.89$4,185,443.07View SEC Filing  
7/14/2014Peter D MeldrumInsiderSell24,000$39.50$948,000.00View SEC Filing  
6/5/2014John T HendersonDirectorSell5,000$35.70$178,500.00View SEC Filing  
5/9/2014Ronald RogersVPSell12,500$36.01$450,125.00View SEC Filing  
4/30/2014Richard MarshVPSell30,000$41.80$1,254,000.00View SEC Filing  
4/23/2014Richard MarshVPSell31,516$39.80$1,254,336.80View SEC Filing  
4/16/2014Richard MarshVPSell28,484$39.80$1,133,663.20View SEC Filing  
4/7/2014Jayne HartVPSell79,000$40.90$3,231,100.00View SEC Filing  
4/2/2014James EvansCFOSell80,000$40.00$3,200,000.00View SEC Filing  
4/2/2014Peter MeldrumInsiderSell55,000$39.57$2,176,350.00View SEC Filing  
3/19/2014Peter MeldrumInsiderSell55,000$37.00$2,035,000.00View SEC Filing  
3/17/2014Peter MeldrumInsiderSell55,000$35.15$1,933,250.00View SEC Filing  
3/12/2014Richard MarshVPSell50,000$34.37$1,718,500.00View SEC Filing  
2/26/2014Walter Phd GilbertDirectorSell30,000$37.58$1,127,400.00View SEC Filing  
2/25/2014Mark Christopher CaponeInsiderSell95,250$37.83$3,603,307.50View SEC Filing  
2/24/2014Gary KingVPSell20,000$38.00$760,000.00View SEC Filing  
2/20/2014James EvansCFOSell30,000$36.01$1,080,300.00View SEC Filing  
2/20/2014Robert Gardner HarrisonInsiderSell17,554$36.22$635,805.88View SEC Filing  
2/19/2014Richard MarshVPSell34,676$34.71$1,203,603.96View SEC Filing  
2/19/2014Walter Phd GilbertDirectorSell60,000$34.48$2,068,800.00View SEC Filing  
2/18/2014Gary KingVPSell25,000$34.74$868,500.00View SEC Filing  
2/18/2014Heinrich DreismannDirectorSell30,000$35.00$1,050,000.00View SEC Filing  
2/14/2014Richard MarshVPSell20,960$31.50$660,240.00View SEC Filing  
2/12/2014Robert Gardner HarrisonInsiderSell13,707$30.74$421,353.18View SEC Filing  
2/10/2014Mark Christopher CaponeInsiderSell87,500$32.07$2,806,125.00View SEC Filing  
2/7/2014James EvansCFOSell35,000$33.04$1,156,400.00View SEC Filing  
2/5/2014Peter MeldrumInsiderSell123,940$31.10$3,854,534.00View SEC Filing  
11/8/2013James EvansCFOSell8,072$26.50$213,908.00View SEC Filing  
11/8/2013Peter MeldrumInsiderSell31,784$26.50$842,276.00View SEC Filing  
6/13/2013Robert Gardner HarrisonInsiderSell31,498$36.17$1,139,282.66View SEC Filing  
5/16/2013Mark Christopher CaponeInsiderSell79,999$33.23$2,658,366.77View SEC Filing  
5/14/2013Peter D MeldrumInsiderSell15,000$34.00$510,000.00View SEC Filing  
5/10/2013Heinrich DreismannDirectorSell30,000$31.16$934,800.00View SEC Filing  
5/10/2013Peter D MeldrumInsiderSell75,960$31.99$2,429,960.40View SEC Filing  
5/10/2013Richard M MarshVPSell48,192$33.00$1,590,336.00View SEC Filing  
10/4/2012Jerry S LanchburyInsiderSell3,900$28.50$111,150.00View SEC Filing  
10/3/2012Jerry S LanchburyInsiderSell3,000$28.50$85,500.00View SEC Filing  
9/14/2012Peter D MeldrumInsiderSell20,000$27.60$552,000.00View SEC Filing  
9/13/2012James S EvansCFOSell5,494$27.10$148,887.40View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Myriad Genetics (NASDAQ:MYGN)
Latest Headlines for Myriad Genetics (NASDAQ:MYGN)
DateHeadline logoMyriad Genetics (MYGN) Granted FDA Acceptance for ... - - October 19 at 6:37 AM logoCompany Expects FDA Priority Review to Conclude in the Fiscal Third-Quarter 2018 - October 18 at 7:23 AM logoETFs with exposure to Myriad Genetics, Inc. : October 17, 2017 - October 18 at 7:23 AM logoMyriad’s BRACAnalysis CDx® Supplementary PMA Accepted by FDA for Review as a Companion Diagnostic for Lynparza® (olaparib) in Metastatic Breast Cancer - October 18 at 7:23 AM logoMyriad Genetics (MYGN) PT Raised to $27 at Piper Jaffray - - October 16 at 5:56 AM logo3 Signs Myriad Genetics' High-Growth Days Are Over - October 13 at 7:11 AM logo3 Signs Myriad Genetics' High-Growth Days Are Over - October 12 at 8:41 AM logoMyriad Genetics, Inc. (MYGN) Expected to Post Quarterly Sales of $182.34 Million - October 8 at 4:04 AM logoMyriad Genetics, Inc. (MYGN) Rating Reiterated by Morgan Stanley - October 7 at 12:00 PM logoETFs with exposure to Myriad Genetics, Inc. : October 6, 2017 - October 7 at 6:22 AM logoAnalysts Offer Predictions for Myriad Genetics, Inc.'s Q1 2019 Earnings (MYGN) - October 6 at 2:28 PM logoMyriad Genetics, Inc. :MYGN-US: Earnings Analysis: Q4, 2017 By the Numbers : October 5, 2017 - October 5 at 10:13 AM logoMyriad Genetics, Inc. Forecasted to Post FY2018 Earnings of $1.03 Per Share (MYGN) - October 4 at 1:56 PM logoMyriad Genetics, Inc. (MYGN) Receives Average Recommendation of "Hold" from Brokerages - October 4 at 6:52 AM logoMyriad Genetics, Inc. Expected to Post Q1 2018 Earnings of $0.20 Per Share (MYGN) - October 3 at 11:20 AM logoMyriad Genetics Highlights Strong Commitment to Preventing and ... - GlobeNewswire (press release) - October 2 at 5:43 PM logoMyriad Genetics, Inc. (MYGN) Now Covered by Analysts at Leerink Swann - October 2 at 10:16 AM logoMyriad Genetics Highlights Strong Commitment to Preventing and Fighting Breast Cancer as Part of Breast Cancer Awareness Month - October 2 at 7:49 AM logoHead to Head Survey: WaferGen Bio-systems (WGBS) & Myriad Genetics (MYGN) - September 28 at 12:36 AM logoImproved Outlook for Myriad Genetics - September 23 at 8:30 AM logoMyriad Genetics' (MYGN) "Overweight" Rating Reiterated at Stephens - September 22 at 9:18 AM logo Brokerages Expect Myriad Genetics, Inc. (MYGN) Will Post Quarterly Sales of $182.22 Million - September 19 at 1:34 AM logoMyriad Genetics Presents Favorable riskScore Test Data - Nasdaq ... - Nasdaq - September 19 at 12:58 AM logoMyriad Genetics' (MYGN) Hold Rating Reaffirmed at Cowen and Company - September 17 at 6:28 AM logoVarex Imaging (VREX) versus Myriad Genetics (MYGN) Financial Review - September 16 at 10:20 PM logoMyriad Genetics Announces Positive Data Supporting New riskScore™ Test at the 36th Annual Conference of the National Society of Genetic Counselors - September 16 at 6:47 AM logoMyriad Genetics, Inc. (MYGN) Short Interest Down 12.9% in August - September 15 at 1:28 AM logoMyriad Genetics to Present Three Studies at the 2017 National Society of Genetic Counselors Annual Conference - September 13 at 6:52 AM logoFinancial Comparison: Varex Imaging (VREX) versus Myriad Genetics (MYGN) - September 13 at 12:40 AM logoMyriad Genetics, Inc. (MYGN) Receives Consensus Rating of "Hold" from Analysts - September 9 at 6:26 AM logoMyriad Genetics (MYGN) Presents At Wells Fargo Healthcare Conference - Slideshow - September 8 at 6:09 AM logoHereditary Cancer Risk Assessment Is an Important Option for Prostate Cancer Patients during Prostate Cancer Awareness Month - September 8 at 6:09 AM logoMyriad Genetics (MYGN) and Sequenom (SQNM) Critical Review - September 7 at 2:20 PM logoMyriad Launches riskScore™ Beginning the Next Epoch in ... - GlobeNewswire (press release) - September 6 at 6:38 AM logoThe 2 Major Catalysts Behind Myriad Genetics, Inc.'s 26% Gain in August - September 6 at 6:37 AM logoMyriad Launches riskScore™ Beginning the Next Epoch in Hereditary Cancer Testing - September 6 at 6:37 AM logoInsider Selling: Myriad Genetics, Inc. (MYGN) Director Sells 30,000 Shares of Stock - September 5 at 4:26 PM logoThe 2 Major Catalysts Behind Myriad Genetics, Inc.'s 26% Gain in August - September 5 at 12:52 PM logoMyriad Genetics (MYGN) & Varex Imaging Corp (VREX) Head to Head Review - September 2 at 12:20 PM logoVarex Imaging (VREX) vs. Myriad Genetics (MYGN) Head-To-Head Comparison - September 1 at 8:20 PM logo5 of the Most Hated Biotech Stocks on the Market: Are They Buys? - September 1 at 1:23 PM logo Brokerages Anticipate Myriad Genetics, Inc. (MYGN) Will Post Quarterly Sales of $182.22 Million - September 1 at 6:04 AM logoMyriad Genetics to Present at the 2017 Morgan Stanley Global Healthcare Conference - August 31 at 7:35 AM logo$0.21 Earnings Per Share Expected for Myriad Genetics, Inc. (MYGN) This Quarter - August 30 at 10:20 AM logoMyriad Genetics to Present at the 2017 Wells Fargo Healthcare Conference - August 30 at 7:02 AM logoMyriad Genetics, Inc. (MYGN) Short Interest Update - August 27 at 4:04 AM logoETFs with exposure to Myriad Genetics, Inc. : August 24, 2017 - August 25 at 8:51 AM logoMyriad Genetics, Inc. (MYGN) Upgraded by Deutsche Bank AG to Hold - August 19 at 11:32 PM logoReviewing Varex Imaging (VREX) & Myriad Genetics (MYGN) - August 19 at 10:48 AM logoMyriad Genetics' EndoPredict Gets Positive Coverage Decision - August 19 at 4:26 AM



Myriad Genetics (MYGN) Chart for Thursday, October, 19, 2017

This page was last updated on 10/19/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.